Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2016, Celgene's Thalomid and Revlimid and Millennium/Johnson & Johnson's Velcade will vie for dominance in the multiple myeloma drug market.
The new Pharmacor report entitled Multiple Myeloma finds that, although Thalomid, Revlimid and Velcade will compete for market leadership, drug- related toxicities and complications suffered by patients with the disease will hinder full market penetration by any one agent. The sales of treatments for multiple myeloma exceeded $1 billion in 2006 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan-a substantial achievement given the low incidence of this niche indication.
"The multiple myeloma field is an active area of clinical research, but there is a distinct lack of mature data currently available for pipeline drugs," said Clair Gricks, Ph.D., analyst at Decision Resources. "Based on available data and expert opinion, we anticipate the launch of five agents through 2016. Additionally, despite recent therapeutic advances, treating physicians still consider multiple myeloma to be incurable in the majority of patients, and they report that the most significant remaining unmet need is for drugs that can improve long-term survival outcome."
About Multiple Myeloma
A form of cancer, multiple myeloma affects plasma cells, which are white blood cells that produce antibodies for fighting infection. The disease can cause tumors to grow in bones and lead to bone pain and fractures. A dramatic change is underway in the treatment practice for multiple myeloma as old style chemotherapy regimens are being abandoned in favor of recently approved immunomodulatory drugs and proteasome inhibitors. Although long-term survival data for these treatments are presently lacking, results so far show an improved efficacy for patients. However, such agents command a premium price, resulting in substantial reimbursement issues and cost constraints across all of the markets under study in this report.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/